Elizabeth Budde: We reported the longest follow-up of using BsAbs in lymphoma

Elizabeth Budde, Associate Professor at City of Hope, shared on X/Twitter:

“We reported the longest follow-up of using BsAbs in lymphoma. With a median 3.5 years follow-up, the DOCR for patients treated with mosunetuzumab is not reached. No relapses post 26 months. Retreatment worked in 10/12 including 7 complete remissions.”

Proceed to the article.
Source: Elizabeth Budde/X